
Astrazeneca Pharma India Ltd is Rated Sell
2026-06-19 10:10:57Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 June 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.
Read full news article
Astrazeneca Pharma India Ltd is Rated Sell
2026-06-08 10:10:23Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Astrazeneca Pharma India Ltd Technical Momentum Shifts Amid Mixed Signals
2026-06-02 08:06:34Astrazeneca Pharma India Ltd has experienced a nuanced shift in its technical momentum, with recent data revealing a transition from a sideways trend to a mildly bearish stance. Despite a modest day gain of 0.61%, the stock’s technical indicators present a complex picture, reflecting both bullish and bearish signals across weekly and monthly timeframes.
Read full news article
Astrazeneca Pharma India Ltd is Rated Sell
2026-05-28 10:10:44Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.
Read full news articleAre Astrazeneca Pharma India Ltd latest results good or bad?
2026-05-27 19:44:56AstraZeneca Pharma India Ltd's latest financial results for Q4 FY26 present a mixed picture, highlighting significant operational challenges alongside notable revenue growth. The company reported net sales of ₹578.61 crores, reflecting a year-on-year growth of 20.42% compared to ₹480.48 crores in Q4 FY25. However, this figure represents a sequential decline of 5.39% from ₹611.57 crores in Q3 FY26, indicating potential seasonal weaknesses or market share challenges. In terms of profitability, AstraZeneca faced considerable pressure. The net profit for the quarter was ₹44.88 crores, which marks a decline of 22.96% quarter-on-quarter and a 22.95% drop year-on-year from ₹58.25 crores in the same quarter last year. This decline in profit occurred despite the strong revenue growth, suggesting that the company is experiencing significant margin compression. The operating margin fell sharply to 10.53%, down from 1...
Read full news article
AstraZeneca Pharma Q4 FY26: Margin Pressure Clouds Strong Revenue Growth
2026-05-27 11:50:20AstraZeneca Pharma India Ltd. reported a challenging quarter for Q4 FY26 (January-March 2026), with net profit declining to ₹44.88 crores, down 22.96% quarter-on-quarter (QoQ) from ₹58.25 crores in Q3 FY26, despite posting robust revenue growth of 20.42% year-on-year (YoY). The stock reacted sharply to the mixed results, declining 5.17% to close at ₹8,520.00 on May 27, 2026, as investors grappled with deteriorating margins and profitability concerns despite the company's strong topline momentum.
Read full news articleWhen is the next results date for Astrazeneca Pharma India Ltd?
2026-05-21 23:18:34The next results date for Astrazeneca Pharma India Ltd is scheduled for 26 May 2026....
Read full news article
Astrazeneca Pharma India Ltd Technical Momentum Shifts Amid Mixed Signals
2026-05-20 08:03:33Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a 2.19% gain on 20 May 2026, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity on the stock’s near-term trajectory.
Read full news article
Astrazeneca Pharma India Ltd is Rated Sell
2026-05-17 10:10:15Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 May 2026, providing investors with an up-to-date view of its performance and outlook.
Read full news articleDisclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management Personnel
16-Jun-2026 | Source : BSEPlease find the enclosed letter of the Company as per the captioned subject for reference.
Closure of Trading Window
15-Jun-2026 | Source : BSEPlease find the enclosed intimation of the Company as per the captioned subject for your reference.
Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Resignation Of Senior Management Personnels
12-Jun-2026 | Source : BSEPlease find the enclosed intimation of the Company with respect to the captioned subject for your reference.
Corporate Actions
No Upcoming Board Meetings
Astrazeneca Pharma India Ltd has declared 1600% dividend, ex-date: 18 Jul 25
Astrazeneca Pharma India Ltd has announced 2:10 stock split, ex-date: 15 Jun 06
No Bonus history available
No Rights history available






